On Tuesday, Shares of YY Inc (ADR)(NASDAQ:YY), included 3.32% and shut at $45.49 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $43.63 and $46.81. YY Inc. (YY) (“YY” or the “Company”), a live streaming platform, recently declared its unaudited financial results for the third quarter of 2016.
Third Quarter 2016 Highlights
Net revenues raised by 40.3% to RMB2,089.8 million (US$313.4 million) from RMB1,490.0 million in the corresponding period of 2015.
Net income attributable to YY raised by 155.8% to RMB400.0 million (US$60.0 million) from RMB156.4 million in the corresponding period of 2015.
Non-GAAP net income attributable to YY raised by 83.7% to RMB435.6 million (US$65.3 million) from RMB237.1 million in the corresponding period of 2015.
“We are extremely happy to have achieved solid results this quarter with both top- and bottom-line growth across the board,” said Mr. Zhou Chen, Chief Executive Officer of YY. “This growth was mainly driven by the robust 54.5% year-over-year growth in our live streaming business, which was made possible through the successful execution of our business and content strategy. Importantly, we continued to focus on the development of PUGC (Professionally-curated User Generated Content) and PGC. In the third quarter of 2016, we launched a new relationships program and further developed our sports content. In Addition To, Huya broadcasting continues to increase its content offerings for mobile game broadcasting and broaden its popularity. Going forward, we will continue to strengthen our content to meet the ever evolving demands of YY’s 98.0 million PC MAU and 53.4 million mobile MAU in the third quarter of 2016. We believe in our ability to build a comprehensive content ecosystem across our two live streaming platforms, YY Live and Huya broadcasting, and are confident that we have the right strategy in place to further fortify our position as China’s leading interactive, live streaming platform.”
Shares of Juno Therapeutics Inc (NASDAQ:JUNO), subtract -4.96% and shut at $29.88 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $29.82 and $31.97. The association’s commercial center capitalization is $3.32 Billion with the general uncommon loads of 105.87 million. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The companys additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.